Here you will find the recommendations we have made about the use of individual medicines in Lancashire.


Brand: Tertroxin®
Indication: Liothyronine as monotherapy for the chronic management of hypothyroidism
Disease category: Endocrine
Commissioning responsibility: CCG
PbR excluded: No


Prescribing within Primary Care — Black

Liothyronine is NOT recommended for use by the NHS in Lancashire in the following setting:

as an add-on treatment for refractory hypothyroidism despite adequate monotherapy with levothyroxine:

There is insufficient evidence to demonstrate efficacy in the above setting, availability of the drug is limited, adverse events are more prevalent than for Levothyroxine monotherapy and there would be a considerable cost pressure to the health economy if prescribed for all patients with normal serum TSH levels and have persistent symptoms.

As monotherapy for the chronic management of hypothyroidism:

There is a paucity of evidence in the literature supporting the use of Liothyronine monotherapy for the management of hypothyroidism. Liothyronine is not licensed for the long-term management of hypothyroidism.


LMMG recommendation: Black
Click here to find the definitions for the colour classifications

Reason for decision:  Not recommended for prescribing on the NHS in Lancashire

Supporting documents:

New Medicine Assessment Liothyronine (475.1 KiB)

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG